Aarti Drugs Limited Announces Unaudited Standalone and Consolidated Financial Results for the Third Quarter and Nine Months Ended December 31, 2017
February 13, 2018 at 05:03 am EST
Share
Aarti Drugs Limited announced unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2017. For the third quarter, on standalone basis, the company's total income was INR 3,083.4 million against INR 2,867.4 million for the same period last year. Profit from operations before other income, finance costs and exceptional items was INR 330.8 million against INR 223.4 million for the same period last year. Profit before tax was INR 330.8 million against INR 223.4 million for the same period last year. Profit for the period was INR 220.3 million against INR 163.4 million for the same period last year. Earnings per share before and after extraordinary items, basic and diluted, were INR 9.23 against INR 6.93 for the same period last year.
For the nine months, on standalone basis, the company's total income was INR 8,449.4 million against INR 8,955.4 million for the same period last year. Profit from operations before other income, finance costs and exceptional items was INR 756.3 million against INR 774.8 million for the same period last year. Profit before tax was INR 756.3 million against INR 774.8 million for the same period last year. Profit for the period was INR 506.3 million against INR 537.8 million for the same period last year. Earnings per share before and after extraordinary items, basic and diluted, were INR 21.22 against INR 22.27 for the same period last year.
For the third quarter, on consolidated basis, the company's total income was INR 3,355.4 million against INR 3,110.6 million for the same period last year. Profit from operations before other income, finance costs and exceptional items was INR 350.3 million against INR 240.9 million for the same period last year. Profit before tax was INR 350.3 million against INR 240.9 million for the same period last year. Profit for the period was INR 233.3 million against INR 178.5 million for the same period last year. Earnings per share before and after extraordinary items, basic and diluted, were INR 9.78 against INR 7.56 for the same period last year. Consolidated EBITDA was INR 540.6 million up by 25.3%.
For the nine months, on consolidated basis, the company's total income was INR 9,321.0 million against INR 9,696.7 million for the same period last year. Profit from operations before other income, finance costs and exceptional items was INR 862.8 million against INR 852.6 million for the same period last year. Profit before tax was INR 756.3 million against INR 774.8 million for the same period last year. Profit for the period was INR 583.1 million against INR 598.6 million for the same period last year. Earnings per share before and after extraordinary items, basic and diluted, were INR 24.44 against INR 24.78 for the same period last year.
Aarti Drugs Limited is an India-based company that is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.
AARTI DRUGS LIMITED 
